Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
![]() |
![]() ![]() |
Ultima descărcare din IBN: 2024-04-07 18:07 |
Căutarea după subiecte similare conform CZU |
[616.831.9-002.1:582.284]:[616.98:578.828.6] (1) |
Neurology. Neuropathology. Nervous system (985) |
Systematic botany (869) |
Communicable diseases. Infectious and contagious diseases, fevers (587) |
Virology (446) |
![]() IAROVOI, Liviu, NAGÎŢ, Angela, MINZATEAN, Nicoleta, MICȘANSCHI, Pavel, COJUHARI, Lilia, BABA, Lilia, LAZĂR, Vasile, HOLBAN, Tiberiu. Meningita criptococică la pacienții infectați cu HIV/SIDA. In: Sănătate Publică, Economie şi Management în Medicină , 2023, nr. 3(96_S), pp. 70-73. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | |||
Numărul 3(96_S) / 2023 / ISSN 1729-8687 /ISSNe 2587-3873 | |||
|
|||
CZU: [616.831.9-002.1:582.284]:[616.98:578.828.6] | |||
Pag. 70-73 | |||
![]() |
|||
Rezumat | |||
O boală infecțioasă importantă pentru sănătatea publică la nivel mondial este criptococcoza. Anual, se estimează că mortalitatea persoanelor care trăiesc cu HIV și primesc îngrijiri pentru meningita criptococică este de 70% în țările cu venituri mici, comparativ cu rata de 20-30% înregistrată în țările cu venituri mari [13]. Ne-am propus drept scop studierea particularităților meningitei criptococice (MC) la pacienții cu infecție HIV. Am analizat retrospectiv-descriptiv fișele de observație ale 14 pacienți infectați cu HIV, care au dezvoltat MC și au fost internați în perioada 2018-2023 la Spitalul de Dermatologie și Boli Comunicabile din Chișinău. Rezultatele acestui studiu sugerează ca nivelul de CD4 sub 20 de celule este asociat finalității nefavorabile a MC la pacienții cu infecție HIV/SIDA. |
|||
Cuvinte-cheie criptococoză, Cryptococcus neoformans, meningită criptococică, infecție cu HIV/SIDA, Cryptococcosis, Cryptococcus neoformans, cryptococcal meningitis, HIV/AIDS infection, криптококкоз, Cryptococcus neoformans, криптококковый менингит, ВИЧ/СПИД-инфекция |
|||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-194097</cfResPublId> <cfResPublDate>2023-12-01</cfResPublDate> <cfVol>96_S</cfVol> <cfIssue>3</cfIssue> <cfStartPage>70</cfStartPage> <cfISSN>1729-8687</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/194097</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Meningita criptococică la pacienții infectați cu HIV/SIDA</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>criptococoză; Cryptococcus neoformans; meningită criptococică; infecție cu HIV/SIDA; Cryptococcosis; Cryptococcus neoformans; cryptococcal meningitis; HIV/AIDS infection; криптококкоз; Cryptococcus neoformans; криптококковый менингит; ВИЧ/СПИД-инфекция</cfKeyw> <cfAbstr cfLangCode='RO' cfTrans='o'><p>O boală infecțioasă importantă pentru sănătatea publică la nivel mondial este criptococcoza. Anual, se estimează că mortalitatea persoanelor care trăiesc cu HIV și primesc îngrijiri pentru meningita criptococică este de 70% în țările cu venituri mici, comparativ cu rata de 20-30% înregistrată în țările cu venituri mari [13]. Ne-am propus drept scop studierea particularităților meningitei criptococice (MC) la pacienții cu infecție HIV. Am analizat retrospectiv-descriptiv fișele de observație ale 14 pacienți infectați cu HIV, care au dezvoltat MC și au fost internați în perioada 2018-2023 la Spitalul de Dermatologie și Boli Comunicabile din Chișinău. Rezultatele acestui studiu sugerează ca nivelul de CD4 sub 20 de celule este asociat finalității nefavorabile a MC la pacienții cu infecție HIV/SIDA.</p></cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'><p>An important infectious illness for worldwide public health is cryptococcosis. The estimated one-year mortality of people living with HIV who receive care for cryptococcal meningitis (СM) is 70% in low-income countries versus 20–30% for high-income countries [13]. In order to study the peculiarities of the evolution of cryptococcal meningitis we conducted a retrospective-descriptive study. All 14 patients included in study during the years 2018-2023 were admitted to the dermatological and Communicable Diseases Hospital in Chisinau. The results of the study suggest that the CD4 level below 20 cells is associated with the unfavorable outcome of MC in patients with HIV/AIDS.</p></cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'><p>Важным инфекционным заболеванием для общественного здравоохранения во всем мире является криптококкоз. По современным оценкам, годовая смертность людей, живущих с ВИЧ, получающих помощь по поводу криптококкого менингита, составляет 70% в странах с низкими доходами по сравнению с 20–30% в странах с высокими доходами [13]. Чтобы изучить особенности эволюции криптококкового менингита, мы провели ретроспективно-описательное исследование. Все 14 пациентов с ВИЧ, включенных в данное исследование, переносящих криптококковый менингит в период с 2018 по 2023 год, были госпитализированы в Больницу Кожных и Трансмиссивных заболеваний г. Кишинева. Результаты исследования предполагают, что уровень CD4 ниже 20 клеток связаны с неблагоприятным исходом для больных с ВИЧ/СПИД-ом переносящих криптококковый менингит.</p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11184</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-16183</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-110346</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-87036</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10995</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-29199</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-114903</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-251</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11184</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11184-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Iarovoi</cfFamilyNames> <cfFirstNames>Liviu</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-16183</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-16183-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Nagîţ</cfFamilyNames> <cfFirstNames>Angela</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-110346</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-110346-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Minzatean</cfFamilyNames> <cfFirstNames>Nicoleta</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-87036</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-87036-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Micșanschi</cfFamilyNames> <cfFirstNames>Pavel</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10995</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10995-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Cojuhari</cfFamilyNames> <cfFirstNames>Lilia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-29199</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-29199-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Baba</cfFamilyNames> <cfFirstNames>Lilia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-114903</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-114903-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Lazăr</cfFamilyNames> <cfFirstNames>Vasile</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-251</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-251-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2023-12-01T24:00:00</cfStartDate> <cfFamilyNames>Holban</cfFamilyNames> <cfFirstNames>Tiberiu</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>